The effectiveness of highly active antiretroviral therapy among HIV-infected children in Asian countries

Asian Biomedicine

Volumn 3, Issue 1, 2009, Pages 89-100

  Bunupuradah, Torsak ^a   Aurpibul, Linda ^b   Ananworanich, Jintanat ^a,c   Puthanakit, Thanyawee ^a,b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c Southeast Asia Research Collaboration with Hawaii (SEARCH)   (Thailand)

Author keywords

Antiretroviral therapy; Asia; Human immunodeficiency virus; Pediatric

Indexed keywords

ABACAVIR; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PREDNISOLONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ANEMIA; ARTICLE; ASIAN; CHILD CARE; COMBINATION CHEMOTHERAPY; DIAGNOSTIC TEST; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INTOXICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTRITIS; HEADACHE; HEALTH CARE ACCESS; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LOW DRUG DOSE; MORTALITY; MUCOSAL DISEASE; NIGHTMARE; PANCREATITIS; PATIENT SELECTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT OUTCOME; VIRUS TRANSMISSION; VIVID DREAM; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 70349392049     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organisation (WHO). Aids epidemic update: November 2007. Available at: http://data.unaids.org/pub/EPISlides/2007/2007-epiupdate-en.pdf.
2. Children and AIDS: stocking report actions and progress. UNICEF 2008. Available at :http://www.unicef.org/media/files/Children-and-AIDS-Second- Stocktaking-Report.pdf. Access Oct 29,2008.
3. United Nations Programme on HIV/AIDS (UNAIDS) 2008 progress reports submitted by countries. Available at: http://www.unaids.org/en/Knowledge Centre/HIVData/CountryProgress/2007Country ProgressAllCountries.asp.
4. PENTA guidelines for the use of antiretroviral therapy in pediatric infection, 2008 draft version, date 1 November 2008.
5. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resourcelimited settings: towards universal access. Geneva: WHO, 2006.
6. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, July 29, 2008. Access at http://AIDSinfo.nih.gov/.
7. Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, et al. Efficacy nd tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis. 2008; 12:e33-8.
8. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Mothi SN, Solomon S. Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India. J Trop Pediatr. 2008; Oct 1 (Epub ahead of print).
9. Lodha R, Upadhyay A, Kabra SK. Antiretroviral Therapy in HIV-1 Infected Children. Indian Pediatr. 2005;42:789-796
10. O'Brien DP, Sauvageot D, Zachariah R, Humblet P. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS (London). 2006;20:1955-1960.
11. O'Brien DP, Sauvageot D, Olson D, Schaeffer M, Humblet P, Pudjades M, et al. Treatment outcomes stratified by baseline immunological status among young children receiving non-nucleoside reversetranscriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis. 2007;44: 1245-1248
12. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjanavanit S, Wannarit P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J. 2007;26:953-956
13. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wannarit P, Sirisanthana T, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107
14. Janssens B, Raleigh B, Soeung S, Akao K, Te V, Gupta J, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics. 2007;120:e1134-40.
15. Saelim T. Clinical Characteristic of Pediatric HIV Infection at Khon Kaen Hospital. Khon Kaen Hospital Med J. 2008;32:489-496
16. Natu SA, Daga SR. Antiretroviral therapy in children: Indian experience. Indian Pediatr. 2007;44:339-343
17. Zhang F, Haberer JE, Zhao Y, Dou Z, Zhao H, He Y, et al. Chinese pediatric highly active antiretroviral therapy observational cohort: a 1-year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr. 2007;46:594-598
18. Bunupuradah T, Puthanakit T, Boonrak P, Butterworth O, Mengthaisong T, Intasan J, et al. Efficacy and safety of non-nucleoside reverse transcriptase inhibitor (NNRTI) based highly active antiretroviral therapy (HAART) in Thai children with HIV. Presented at 4th IAS conference, Sydney, 2007; poster No. TUPEB128.
19. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, et al. Safety and efficacy of double boosted protease inhibitors, saquinavir and lopinavir/ritonavir, in pre-treated children at 96 weeks antiviral therapy. Antiviral Therapy; 2009; in press.
20. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J. 2007;26:86-88
21. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J. 2008;27:623-628
22. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J. 2005;24:874-879
23. Van der Lugt J, Puthanakit T, Gorowara M, Bunupuradah T, Butterworth O, Phasomsap C, Jupimai T, ancharoen C, D.M. Burger, Ruxrungtham K. Low dose of the HIV-protease inhibitor Lopinavir provides adequate plasma concentrations in Thai children. Presented at 9th Workshop on Clinical Pharmacology of HIV Therapy, New Orleans, 2008.
24. Puthanakit T, Aurpibul L, Oberdorfer P, Akarathum N, Kanjananit S, Wannarit P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis. 2007;44:599-604. (Pubitemid 46233267)
25. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus- infected Thai children. Pediatr Infect Dis J. 2006;25:53-58
26. De Luca M, Miccinesi G, Chiappini E, Zappa M, Galli L, De Martino M. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. Interna J Immunopathol Pharmacol. 2005;18:729-735
27. Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai. 2005;88:956-66
28. Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV-infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai. 2005;88:956-66. 28. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antiviral Therapy. 2007;12: 1247-1254
29. Lee B, Aurpibul L, Sirisanthana V, Mangklabruks A, Sirisanthana T, Puthanakit T. Low prevalence of insulin resistance among HIV-infected children receiving non-nucleoside reverse transcriptase inhibitor- ased highly active antiretroviral therapy in Thailand. HIV Medicine. 2008; Epub ahead of print.
30. Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged 2 years or less. Pediatr Infect Dis J. 2009; in press.
31. Chokephaibulkit K, Vanprapar N, Sutthent R, Phongsamart W, Chotpitayasunondh T, Bowornkitikajorn P, et al. Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource- limited setting: a multi-center study in Thailand 1998-2000. J Med Assoc Thai. 2005;88(SUPPL. 8):S1-8.
32. Collaboration"TK-A-L. Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2008; in press.
33. Chantry CJ, Byrd RS, Englund JA, Baker CJ, McKinney RE, Jr. Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J. 2003;22:1033-1039
34. Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatric Infect Dis J. 2005;24:352-357
35. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS. 2008;22:245-251
36. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA, Richardson BA, et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr. 2007;45:311-317
37. Jaspan HB, Berrisford AE, Boulle AM. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Pediatr Infect Dis J. 2008;27:993-998
38. Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics. 2007;120:e856-61.
39. Pujari SN, Patel AK, Naik E, Patel KK, Dravid A, Patel JK, et al. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J Acquir Immun Defic Syndr. 2004; 37:1566-1569
40. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224 (Pubitemid 40962502)
41. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai. 2004;87:760-767
42. L'Homme R F, Kabamba D, Ewings FM, Mulenga V, Kankasa C, Thomason MJ, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS. 2008;22:557-565
43. Bertolli J, Hsu HW, Sukalac T, Williamson J, Peters V, Frederick T, et al. Hospitalization trends among children and youths with perinatal human immunodeficiency virus infection, 1990-2002. Pediatr Infect Dis J. 2006;25:628-633
44. Paul S, Gilbert HM, Ziecheck W, Jacobs J, Sepkowitz KA. The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS. 1999;13:415-418
45. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:725-731
46. Sanchez JM, Ramos AJT, Fernandez MS, Gonzalez TMI, Rojo CP, Ferrnado VP, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virusinfected children. Pediatr Infect Dis J. 2003;22:863-867
47. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Intern J Epidemiol. 2007;36: 1009-1021